trending Market Intelligence /marketintelligence/en/news-insights/trending/jvi1fk6lmah6zja8jx3-lq2 content esgSubNav
In This List

Impax to pay $20M to consumers, insurers in Solodyn antitrust case

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Impax to pay $20M to consumers, insurers in Solodyn antitrust case

Impax Laboratories Inc. agreed to pay $20 million to consumers and insurers to resolve claims in an antitrust lawsuit related to Valeant Pharmaceuticals International Inc.'s acne medication Solodyn, Reuters reported.

The lawsuit, a portion of which was settled by the Hayward, Calif.-based pharmaceutical company earlier this month, alleged that Impax was involved in a pay-for-delay deal which kept cheaper versions of Solodyn from entering the market.

The accord was disclosed in papers filed in federal court in Boston, the news outlet added.